Results 11 to 20 of about 148,561 (252)
Therapeutics and Clinical Risk Management, 2015 Yolande B Saab,1 Rony Zeenny,2 Wijdan H Ramadan2 1School of Pharmacy, Pharmaceutical Sciences Department, 2School of Pharmacy, Pharmacy Practice Department, Lebanese American University, Byblos, Lebanon Purpose: Response to clopidogrel varies widely with
Saab YB, Zeenny R, Ramadan WH
doaj +1 more source
Clopidogrel resistance: The way forward
Indian Heart Journal, 2014 Clopidogrel, a second generation thienopyridine has been the mainstay of ACS (Acute Coronary Syndrome) treatment for more than a decade. Clopidogrel Resistance has been associated with increased mortality in ACS patients with an increase in number of ...
Shuvanan Ray
doaj +2 more sources
Therapeutics and Clinical Risk Management, 2015 Zhi-Yu Wang,1 Meng Chen,1 Ling-Ling Zhu,2 Lu-Shan Yu,3 Su Zeng,3 Mei-Xiang Xiang,4 Quan Zhou1 1Department of Pharmacy, 2VIP Care Ward, Division of Nursing, the Second Affiliated Hospital, School of Medicine, 3Department of Pharmaceutical Analysis and ...
Wang ZY +6 more
doaj +1 more source
Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC) [PDF]
, 2018 The P2Y12 receptor inhibitor clopidogrel is widely used in patients with acute coronary syndrome, percutaneous coronary intervention, or ischemic stroke.
International Clopidogrel Pharmacogenomics Consortium
core +2 more sources
Drug interactions and hepatotoxicity of clopidogrel [PDF]
, 2010 Clopidogrel (Plavix¨) is an antiplatelet drug, which is clinically used in combination with aspirin to reduce cardiovascular events in patients undergoing percutaneous coronary intervention or in patients suffering from acute coronary syndromes ...
Zahno, Anja-Christina
core +1 more source
Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction--a hospital registry-primary care linked cohort (MINAP-GPRD). [PDF]
, 2011 AIMS: Adherence to evidence-based treatments and its consequences after acute myocardial infarction (MI) are poorly defined. We examined the extent to which clopidogrel treatment initiated in hospital is continued in primary care; the factors predictive ...
Van Staa, Tjeerd; id_orcid +25 more
core +1 more source
Drug resistance with monitored adherence [PDF]
, 2013 Drug resistance can be defined as the failure of a drug to exert its expected effect on pharmacological biomarkers and is caused by pharmacogenetic, cellular or clinical factors.
Walter, Philipp Niklaus
core +1 more source
Рациональная фармакотерапия в кардиологии, 2015 Aim. To study prevalence of resistance to acetylsalicylic acid, clopidogrel and dual resistance in percutaneous coronary intervention (PCI), to identify clinical risk factors of resistance development, to study effects of concomitant therapy on ...
V. A. Sulimov, E. V. Moroz
doaj +3 more sources
A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI
Indian Heart Journal, 2015 Background: A thorough understanding of the patient's genotype and their functional response to a medication is necessary for improving event free survival.
P.C. Rath +9 more
doaj +1 more source
Scientific Reports, 2021 Clopidogrel is converted to its active metabolite by cytochrome P450 isoenzymes and irreversibly inhibits platelet activation by antagonizing the adenosine-diphosphate (ADP) receptor.
Yu Ueda +8 more
doaj +1 more source